<code id='2C6EFB74CF'></code><style id='2C6EFB74CF'></style>
    • <acronym id='2C6EFB74CF'></acronym>
      <center id='2C6EFB74CF'><center id='2C6EFB74CF'><tfoot id='2C6EFB74CF'></tfoot></center><abbr id='2C6EFB74CF'><dir id='2C6EFB74CF'><tfoot id='2C6EFB74CF'></tfoot><noframes id='2C6EFB74CF'>

    • <optgroup id='2C6EFB74CF'><strike id='2C6EFB74CF'><sup id='2C6EFB74CF'></sup></strike><code id='2C6EFB74CF'></code></optgroup>
        1. <b id='2C6EFB74CF'><label id='2C6EFB74CF'><select id='2C6EFB74CF'><dt id='2C6EFB74CF'><span id='2C6EFB74CF'></span></dt></select></label></b><u id='2C6EFB74CF'></u>
          <i id='2C6EFB74CF'><strike id='2C6EFB74CF'><tt id='2C6EFB74CF'><pre id='2C6EFB74CF'></pre></tt></strike></i>

          hotspot

          hotspot

          author:explore    Page View:5577
          HHS 2020
          PhRMA is suing the Biden administration over its new Medicare drug price negotiation program. Graeme Sloan/Sipa USA

          WASHINGTON — After losing the drug pricing fight on Capitol Hill, PhRMA is taking its battle to the courts.

          The pharmaceutical industry’s biggest lobbying group on Wednesday filed a long-expected lawsuit challenging Democrats’ drug pricing law that allowed Medicare to start negotiating prices for certain medicines.

          advertisement

          PhRMA joins a growing club of companies and trades challenging the law. Merck, Bristol Myers Squibb, and the Chamber of Commerce have already filed similar suits in different courts.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In

          focus

          Supreme Court strikes down use of affirmative action
          Supreme Court strikes down use of affirmative action

          ActivistsdemonstratedastheSupremeCourtheardoralargumentsonapairofaffirmativeactioncasesinOctober2022

          read more
          UCB departs biotech trade group BIO
          UCB departs biotech trade group BIO

          AdobeWASHINGTON— UCBleftBIOattheendof2023,thesecondmajormembercompanytoexitafterPfizerpulledoutaswel

          read more
          How to save PrEP access — and even expand it
          How to save PrEP access — and even expand it

          UndertheAffordableCareAct,healthinsurersarerequiredtocoverallcostsassociatedwithpreventivecare—inclu

          read more

          Readout Newsletter: Allogene's pivot, Illumina exec to lead Delfi

          AdobeWanttostayontopofthescienceandpoliticsdrivingbiotechtoday? Signup togetourbiotechnewsletterinyo